CorMedix Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the Securities and Exchange Commission on November 12, 2026, reporting a net loss of $14.7 million for the third quarter and net income of $49.9 million for the nine-month period.
Key Highlights
- Q3 2026 net loss: The company reported a net loss of $14,722 thousand for the three months ended September 30, 2026, compared to net income of $108,563 thousand in the same period of 2025.
- Product sales decline: Net product sales for Q3 2026 were $48,622 thousand, down from $101,547 thousand in Q3 2025; nine-month product sales rose to $264,879 thousand from $180,365 thousand year-over-year.
- Total revenue and grant income: Total revenue and grant income for the nine months ended September 30, 2026 was $283,877 thousand, compared to $183,094 thousand for the same period in 2025.
- Cash position: Cash and cash equivalents stood at $355,150 thousand as of September 30, 2026, up from $144,837 thousand at December 31, 2025.
- Accumulated deficit reduced: The accumulated deficit narrowed to $126,708 thousand at September 30, 2026, from $176,575 thousand at December 31, 2025.
- Total assets: Total assets were $917,745 thousand as of September 30, 2026, compared to $826,142 thousand at December 31, 2025.
- Shares outstanding: As of November 9, 2026, the company had 79,537,626 shares of common stock outstanding.
CorMedix Q3 2026 Financial Results: Quarterly Loss Amid Nine-Month Profitability
According to the filing, CorMedix Inc. (NASDAQ:CRMD) reported a net loss of $14,722 thousand for the three months ended September 30, 2026, a sharp reversal from net income of $108,563 thousand in Q3 2025. The company attributed the quarterly loss in part to a change in contingent consideration of negative $11,543 thousand and a tax benefit of $1,726 thousand in the quarter. Total revenue and grant income for Q3 2026 was $54,519 thousand, down from $104,276 thousand in the prior-year quarter, with net product sales declining to $48,622 thousand from $101,547 thousand. Contract revenue was $2,642 thousand and grant income was $3,255 thousand in the quarter.
For the nine months ended September 30, 2026, the company reported net income of $49,867 thousand and total revenue and grant income of $283,877 thousand, compared to net income of $149,035 thousand and total revenue and grant income of $183,094 thousand in the same period of 2025. Gross profit for the nine-month period was $212,252 thousand, while total operating expenses were $112,303 thousand, resulting in income from operations of $99,949 thousand, according to the filing. Amortization of intangibles for the nine months was $30,900 thousand. Basic net income per common share for the nine months was $0.63 and diluted was $0.57.
On the balance sheet, the filing disclosed total assets of $917,745 thousand and total stockholders' equity of $461,706 thousand as of September 30, 2026. Convertible senior notes, net of deferred financing costs, were $145,421 thousand. During Q3 2026, the company raised $10,141 thousand through ATM sales of common stock and $1,789 thousand from options exercised, according to the statements of changes in stockholders' equity. The company is classified as a non-accelerated filer and is incorporated in Delaware.
What Was Disclosed
CorMedix filed a quarterly report covering the three and nine months ended September 30, 2026, disclosing a Q3 net loss of $14,722 thousand, nine-month net income of $49,867 thousand, cash of $355,150 thousand, and total assets of $917,745 thousand, with 79,537,626 shares outstanding as of November 9, 2026.



Please wait processing your request...